RNS Number : 6782T Renalytix AI PLC 21 July 2020         Renalytix AI plc   Closing of Global Offering and resulting total voting rights   Renalytix AI plc   (LSE : RENX) (NASDAQ: RNLX) (" RenalytixAI " or the " Company "), an artificial intelligence -enabled   in vitro   diagnostics company,

RNS Number : 3256T Renalytix AI PLC 17 July 2020         This announcement contains inside information   Not for release, publication or distribution, in whole or in part, in or into or from any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction  

Download  full announcement Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled  in vitro  diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces that all resolutions proposed at the

Download  full announcement Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled  in vitro  diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, today announces the commencement of an underwritten

Download  full announcement NEW YORK, 8 July, 2020  – Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces that it now

Download  full announcement   Expands access and coverage of  KidneyIntelX™  into key regions for commercial growth Renalytix AI plc  (LSE: RENX), an artificial intelligence-enabled  in vitro  diagnostics company focused on optimizing clinical management of kidney disease to drive improved patient

Download  full announcement Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled  in vitro  diagnostics company focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces a  partnership with the University of

Download  full announcement Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled  in vitro  diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, today announces the public filing of a registration

Download  full announcement Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled  in vitro  diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces proposed board changes together with the

Download  full announcement Renalytix AI plc  (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces that it has received a clinical laboratory